🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

101,14 USD

Máx. histórico

123,62

846 días

Caída desde máximo

-18,18%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,34%

Cierre anterior

100,80

Rango de hoy

100,88 – 101,27

Volumen hoy

1.095.277

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,43%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,37 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 12 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/02/2023 59,60 60,20 58,07 58,27 -2,43% 3,57% 860.400
17/02/2023 59,90 60,16 58,81 59,72 -0,22% 2,25% 524.500
16/02/2023 59,25 60,82 58,69 59,85 -0,30% 3,60% 765.100
15/02/2023 57,52 60,49 57,25 60,03 +3,82% 5,64% 627.500
14/02/2023 57,86 58,79 57,26 57,82 -0,55% 2,64% 973.400
13/02/2023 58,49 58,76 57,51 58,14 -0,22% 2,14% 753.100
10/02/2023 58,47 58,74 57,56 58,27 -0,94% 2,02% 560.300
09/02/2023 59,25 60,24 58,44 58,82 -0,15% 3,04% 1.037.500
08/02/2023 59,59 60,62 58,85 58,91 -1,85% 2,97% 1.000.300
07/02/2023 59,73 60,32 58,42 60,02 +0,00% 3,18% 978.700
06/02/2023 60,80 61,85 59,14 60,02 -1,28% 4,46% 1.099.800
03/02/2023 59,82 60,93 59,76 60,80 +0,23% 1,96% 829.900
02/02/2023 59,35 60,74 59,27 60,66 +3,44% 2,48% 1.004.000
01/02/2023 57,61 59,11 56,86 58,64 +1,98% 3,91% 1.016.400
31/01/2023 56,50 57,58 56,26 57,50 +2,19% 2,34% 777.300
30/01/2023 55,81 56,73 55,35 56,27 +0,12% 2,46% 720.500
27/01/2023 55,57 56,72 55,05 56,20 +0,64% 3,00% 596.500
26/01/2023 55,36 55,94 55,00 55,84 +2,18% 1,71% 539.100
25/01/2023 54,33 54,75 53,58 54,65 +0,00% 2,15% 418.900
24/01/2023 54,52 55,66 53,72 54,65 +0,11% 3,56% 525.500
23/01/2023 53,64 54,84 53,38 54,59 +2,19% 2,73% 651.600
20/01/2023 54,97 55,56 53,37 53,42 -1,84% 3,98% 1.524.200
19/01/2023 55,32 56,03 53,94 54,42 -1,68% 3,78% 1.409.800
18/01/2023 54,30 55,40 53,24 55,35 +2,41% 3,99% 1.119.900
17/01/2023 52,97 54,58 52,20 54,05 +1,83% 4,48% 1.220.000
13/01/2023 51,02 53,23 50,87 53,08 +3,45% 4,63% 1.319.700
12/01/2023 50,25 52,16 49,87 51,31 +2,54% 4,56% 1.011.300
11/01/2023 48,28 50,07 47,76 50,04 +3,67% 4,78% 1.199.800
10/01/2023 48,18 48,97 47,65 48,27 +1,07% 2,73% 719.000
09/01/2023 49,12 49,63 47,46 47,76 -1,49% 4,42% 1.103.800